How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) posted its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the business earned ($0.60) earnings per share.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , Micron Technology (MU) , VBI Vaccines (VBIV) , Amarin (AMRN) , Aldeyra Therapeutics (ALDX) , Allena Pharmaceuticals (ALNA) , Anavex Life Sciences (AVXL) , Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA) .

NASDAQ:AGTC

Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free AGTC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.39
▼
$0.39
50-Day Range: $0.37
▼
$0.42
52-Week Range: $0.23
▼
$2.83

Volume: N/A
Average Volume: 943,490 shs
Market Capitalization: $26.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Applied Genetic Technologies alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Applied Genetic Technologies Stock (NASDAQ:AGTC)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

AGTC Stock News Headlines

February 8, 2024 | finance.yahoo.com

Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa

January 5, 2024 | marketwatch.com

Metagenomi Technologies Files for Initial Public Offering

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 18, 2023 | msn.com

A new mathematical language for biological networks

October 23, 2023 | investing.com

Genetic Technologies (GENE) Earnings Dates & Reports

June 12, 2023 | lse.co.uk

Syncona launches new gene therapy company with GBP96 million funding

June 1, 2023 | msn.com

New AI tool searches genetic haystacks to find disease-causing variants

May 17, 2023 | uk.finance.yahoo.com

Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

May 1, 2023 | usnews.com

Applied Technology Center

April 27, 2023 | finance.yahoo.com

AAV Vectors in Gene Therapy Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain

April 21, 2023 | msn.com

World-first technology from biomodal enables reading of genetic and epigenetic information using existing sequencers

April 1, 2023 | nbcnews.com

Elephant in the dining room: Startup creates mammoth meatball

March 22, 2023 | bbc.co.uk

Genetic control of metabolism

March 16, 2023 | bbc.co.uk

Genetic testing and cystic fibrosis

January 31, 2023 | yahoo.com

Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

January 5, 2023 | thestreet.com

Applied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen Deal

November 28, 2022 | finance.yahoo.com

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

November 22, 2022 | finance.yahoo.com

*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*

November 15, 2022 | finance.yahoo.com

Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022

November 3, 2022 | finance.yahoo.com

Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022

October 25, 2022 | finance.yahoo.com

Florida investment firm looks to take Cambridge gene therapy startup private

October 24, 2022 | lse.co.uk

Syncona to acquire retinal therapy firm Applied Genetic Technologies

October 23, 2022 | finance.yahoo.com

Syncona to Acquire Applied Genetic Technologies Corporation

October 18, 2022 | markets.businessinsider.com

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

September 30, 2022 | msn.com

HC Wainwright & Co. Maintains Buy Rating for Applied Genetic: Here's What You Need To Know

September 23, 2022 | fool.com

Applied Genetic Technologies (NASDAQ: AGTC)

See More Headlines

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/19/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AGTC
CUSIP: N/A
CIK: 1273636
Web: www.agtc.com
Phone: (386) 462-2204
Fax: N/A
Employees: 83
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,940,000.00
Net Margins: N/A
Pretax Margin: -21,537.54%
Return on Equity: -192.90%
Return on Assets: -92.54%

Debt

Debt-to-Equity Ratio: 0.39
Current Ratio: 1.40
Quick Ratio: 1.40

Sales & Book Value

Annual Sales: $320,000.00
Price / Sales: 83.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.26 per share
Price / Book: 1.51

Miscellaneous

Outstanding Shares: 67,632,000
Free Float: 64,859,000
Market Cap: $26.62 million
Optionable: Optionable
Beta: 1.55

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Ms. Susan B. Washer (Age 61)
Pres, CEO & Director
Comp: $747.84k
Mr. Jonathan I. Lieber M.B.A. (Age 52)
Chief Financial Officer
Comp: $533.14k
Dr. Susan Schneider M.D. (Age 64)
Chief Medical Officer
Comp: $480.32k
Dr. Nicholas Muzyczka
Co-Founder
Dr. Barry J. Byrne M.D.
Ph.D., Co-Founder
Dr. William W. Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Board
Dr. Richard Jude Samulski Ph.D.
Co-Founder
Dr. Terence R. Flotte M.D.
Co-Founder
Mr. Gerald Anthony Reynolds
Chief Accounting Officer, Principal Accounting Officer & Treasurer
Dr. Abraham Scaria Ph.D. (Age 63)
Chief Scientific Officer

Key Competitors

View All Competitors

AGTC Stock Analysis - Frequently Asked Questions

How were Applied Genetic Technologies' earnings last quarter?: Applied Genetic Technologies Co. (NASDAQ:AGTC) posted its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the business earned ($0.60) earnings per share.
What other stocks do shareholders of Applied Genetic Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

This page (NASDAQ:AGTC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

About Applied Genetic Technologies Stock (NASDAQ:AGTC)

AGTC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AGTC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info